ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Novel bacteriophages effectively target multidrug-resistant clinical isolates of Klebsiella pneumoniae.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Temperature-dependent coliphage induces distinct temporal bacterial morphological dynamics during infection.Microbiology spectrum · 2026Article
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe global rise in multidrug-resistant (MDR) Klebsiella pneumoniae, a critical ESKAPE pathogen, has outpaced the development of effective antibiotics. Bacteriophage therapy offers a promising alternative, but therapeutic candidates must be carefully selected for broad activity, genetic safety, synergistic cocktail performance, and clinical stability.
methodsWe isolated and characterized six novel lytic phages (vB_Kpn_AM.K1 to vB_Kpn_AM.K6) targeting K. pneumoniae by assessing morphology, host range, growth kinetics, physicochemical stability, and resistance frequency. Genomes were sequenced to confirm absence of lysogeny and virulence genes. Infection dynamics was visualized via fluorescence microscopy. Phage activity was tested across 60 different MDR K. pneumoniae clinical isolates, obtained from diverse sources such as blood, sputum, occult feces, urine etc.
resultsAll six isolated phages were identified as novel dsDNA phages belonging to Caudoviricetes, with genome sizes ranging from 111 to 169 Kbp, devoid of virulence and AMR genes and demonstrating strong bacteriolytic activity. Growth kinetics indicated burst sizes varying from 12-148 PFU/infected cell. The phages displayed stability between 4-50°C, pH 4 -10 and sustained complete activity after lyophilization. More significantly, the phages and their cocktail combinations could effectively kill 93% of MDR K. pneumoniae clinical isolates.
conclusionThese findings establish a panel of genetically safe, phenotypically diverse phages with broad and synergistic activity against MDR K. pneumoniae. The unique replication phenotypes and formulation stability highlight their potential for therapeutic development and deployment in clinical or resource-limited settings.
Indexed as
Identifiers
41105330What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.